Logo
Saturday, 21 May 2022
Logo
The News and Media Division of The Insight Partners
Tuesday, 04 Feb 2020 07:00 pm

OncoWatch: Artificial Intelligence System Shows Accurate Prostate Cancer Results

A recent study led by Karolinska Institute of Sweden, indicated that an Artificial Intelligence (AI) system had considerably been proved more accurate than biopsy in terms of determining cancer & length of tumor from a sample. In addition, the AI system was as good as almost 23 leading uropathologists across the world in calculating the Gleason score, which is one of the most essential prognostic marker for the prostate cancer.

newsImage
 

The Artificial Intelligence system for determining prostate cancer has been developed by a team that had previously launched the new blood-based prostate cancer diagnostic test called Stockholm3. Stockholm3 actually doubles the number of aggressive cancer cells identified, at the same time it also reduces number of unnecessary biopsies by almost 50 percent as compared to the existing clinical procedure with PSA. Stockholm3 is as of now been used in clinical procedures in Sweden, Finland, Norway and Denmark.

EIT (Eastern Institute of Technology) Health has aided in accelerating the development and implementation of Stockholm3 as well as the new AI system named as OncoWatch, by the means of network & financial backing. The OncoWatch will now be sent for validation in nine countries multicenter in order to assess its accuracy across different labs and in a wide-ranging digital pathology scanners, as a part of its development.

The researchers’ from the institute held that prostate cancer diagnostics demands for high-quality devices and with the new AI system that have probably proven pioneering test to the global market. The test for Stockholm3 was used in 20,000 plus men within the Nordics alone last year and OncoWatch is also expected for a strong uptake.

Prostate cancer is amongst most commonly diagnosed cancer in men especially across the Europe, with more than 450,000 new cases been reported every single year. Thus, OncoWatch will enable diagnosis followed by treatment of the aggressive prostate cancer, which is key to survival.  

 

Tags Artificial Intelligence OncoWatch EIT Health Medical Device Cancer Stockholm3 Uropathologists Biopsy

Neha Pandey

Aware of her elements, Neha writes the best articles across industries including electronics & semiconductors, automotive & transportation and food & beverages. Being from the finance background she has the ability to understand the dynamics of every industry and analyze the news updates to form insightful articles. Neha is an energetic person interested in music, travel, and entertainment. Since past 5 years, she written extensively on sectors like technology, finance and healthcare.


Smarter Decisions with Smart News

Smart Market News is committed to getting its readers the latest updates and insights on industries that help in making “smarter” business decisions. With insights and inputs from corporate decision makers, we bring you the stories of adopting innovative solutions and strategies that have been changing the world. Our editorial insights on products, solutions, companies, and adoption of best practices not only help in understanding the markets better, but also prove to be a complete package for your information needs.

media@smartmarketnews.com | sales@smartmarketnews.com

Contact Us
Subscribe to our newsletter
Get the latest in your inbox weekly Sign up for the fully charged newsletter

A PHP Error was encountered

Severity: Notice

Message: Undefined index: csrf_token

Filename: include/footer.php

Line Number: 149

Backtrace:

File: /home/smartmarketnews/public_html/application/views/include/footer.php
Line: 149
Function: _error_handler

File: /home/smartmarketnews/public_html/application/views/news_details.php
Line: 798
Function: view

File: /home/smartmarketnews/public_html/application/controllers/News_controller.php
Line: 227
Function: view

File: /home/smartmarketnews/public_html/index.php
Line: 315
Function: require_once

">
Follow Us:
© The News and Media Division of The Insight Partners 2019 | All Rights Reserved | Privacy Policy